Last reviewed · How we verify
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not (ERMIT)
This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet reactivity compared to standard of care with ticagrelor alone.
Details
| Lead sponsor | University Hospital, Caen |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 128 |
| Start date | Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Mar 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- ST-elevation Myocardial Infarction
Interventions
- cangrelor perfusion during PCI
- standard PCI
Countries
France